Seoul – October 12, 2026 -- Lunit (KRX: 328130) has partnered with Discovery Life Sciences, a lab that supports more than 350 active clinical trial programs, to roll out the Lunit SCOPE suite across biopharmaceutical research.

The AI-powered pathology platform will run inside Discovery's biomarker and tissue analysis workflows. Both companies will tailor it to each client program's design, working directly with pharmaceutical and biotechnology customers.